Docoh
Loading...

ENZN Enzon Pharmaceuticals

Filed: 4 May 21, 4:06pm

 

Exhibit 32.1

 

CERTIFICATION PURSUANT TO 

18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION  906 OF THE SARBANES-OXLEY ACT OF 2002

 

In connection with the Quarterly Report of Enzon Pharmaceuticals, Inc. (the Company) on Form 10-Q for the quarterly period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Richard L. Feinstein, Chief Executive Officer, Chief Financial Officer and Secretary of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

 

 1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

 2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. 

 

May 4, 2021/s/ Richard L. Feinstein
 Richard L. Feinstein
 Chief Executive Officer, Chief Financial Officer and Secretary
 (Principal Executive Officer and Principal Financial Officer)

 

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to Enzon Pharmaceuticals, Inc. and will be furnished to the Securities Exchange Commission or its staff upon request.